CCA
BHVN icon

Cadent Capital Advisors’s Biohaven BHVN Stock Holding History

Cadent Capital Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-35,449
Closed -$1.77M – 155
2024
Q3 		$1.77M Buy
+35,449
New +$1.38M 0.54% 40

Other funds holding BHVN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Cadent Capital Advisors's BHVN Position: Q4 2024 in Review

Cadent Capital Advisors sold out of Biohaven (BHVN) in Q4 2024, closing a stake of 35,449 shares — an estimated $1.77M sold.

Cadent Capital Advisors first reported a position in BHVN in Q3 2024 and held it in 1 quarter. The position peaked at $1.77M in Q3 2024. 256 funds tracked by Wall St. Rank hold BHVN as of Q4 2024.

  • Cadent Capital Advisors reported no remaining Biohaven position as of Q4 2024 after selling out during the quarter.
  • Cadent Capital Advisors sold 35,449 Biohaven shares in Q4 2024, an estimated $1.77M.
  • Cadent Capital Advisors first reported a position in Biohaven in Q3 2024 and held it in 1 quarter.
  • Cadent Capital Advisors's Biohaven position peaked at $1.77M in Q3 2024.
  • 256 funds tracked by Wall St. Rank held Biohaven as of Q4 2024.

Based on Cadent Capital Advisors's 13F filing for Q4 2024, filed 13 Jan 2025.